Hormones and neurotransmitters

 

Barth C, Villringer A, Sacher J: Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition peri- ods. Frontiers in Neuroscience 2015;9:37. Published 2015 Feb 20. doi:10.3389/ fnins.2015.00037

Becker JB: Direct effect of 17 beta-estradiol on striatum: sex differences in dopamine release. Synapse 1990;5:157–164.

Biegon A, McEwen B: Modulation by estradiol of serotonin receptors in the brain. The Rockefeller University, New York, New York. The Journal of Neuroscience 1982, Vol 2, No 2 pp, 199–205.

Birdsall TC: 5-Hydroxytryptophan: a clinically- effective serotonin precursor. Alternative Medicine Review 1998 Aug;3(4):271–80.

Bossé R, DiPaolo T: The modulation of brain dopamine and GABAA receptors by estradiol: a clue for CNS changes occur- ring at menopause. Cell Mol Neurobiol 1996;16:199–212.

Brinton RD: Investigative models for determi- ning hormone therapy – induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action. Ann N Y Acad Sci 2005;1052:57–74. https://pubmed.ncbi.nlm.nih.gov/23615639/

Chavez C, Hollaus M, Scarr E, Pavey G, Gogos A, van den Buuse M: The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: an autoradio- graphy study. Brain Res 2010;1321:51–59.

Compton J, Travis MJ, Norbury R, Erlandsson K, van Amelsvoort T, Daly E, et al: Longterm estrogen therapy and 5-HT2A receptor binding in postmenopausal women; a single photon emission tomography (SPET) study. Horm Behav 2008;53:61–68.

 Cornelius Schüle, Caroline Nothdurfter, Rainer Rupprecht, The role of allopregnanolone in depression and anxiety, Progress in Neurobiology, Volume 113, 2014, de Lignières B. Oral micronized progesterone. Clin Ther. 1999 Jan;21(1):41-60; discussion 1-2. doi: 10.1016/S0149-2918(00)88267-3. PMID: 10090424.

Darj, S. Nilsson, O. Axelsson, D. Hellberg, Clinical and endometrial effects of oestradiol and progesterone in post-menopausal women, Maturitas, Volume 13, Issue 2, 1991, Pages 109-115

De Novaes Soares: ”Efficacy  of  estradiol for the treatment of depressive disorders in perimenopausal women: a double blind ran- domized placebo controlled trial.” Archives of General Psychiatry juni 2001;58(6):529– 534. https://pubmed.ncbi.nlm.nih.gov/15545330/

Dwyer JB, Aftab A, Radhakrishnan R, Widge A, Rodriguez CI, Carpenter LL, Nemeroff CB, McDonald WM, Kalin NH; APA Council of Research Task Force on Novel Biomarkers and Treatments. Hormonal Treatments for Major Depressive Disorder: State of the Art. Am J Psychiatry. 2020 Aug 1;177(8):686-705. doi: 10.1176/appi.ajp.2020.19080848. Epub 2020 May 27. Erratum in: Am J Psychiatry. 2020 Jul 1;177(7):642. Erratum in: Am J Psychiatry. 2020 Oct 1;177(10):1009. PMID: 32456504; PMCID: PMC7841732.

Freeman EW. Depression in the menopause transition: risks in the changing hormone milieu as observed in the general population. Womens Midlife Health. 2015 Aug 11;1:2. doi: 10.1186/s40695-015-0002-y. PMID: 30766689; PMCID: PMC6214217.

Gleaso CE, Dowling NM, Wharton W, et al: Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-Cognitive and Affective Study. PLoS Med. 2015;12(6):e1001833.

Gold EB, Sternfeld B, Kelsey JL, et al: Rela- tion of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40–55 years of age. Am J Epide- miol 2000; 152:463–73.

Gordon JL et al: Efficacy of transdermal estradiol and  micronized  progesterone  in the prevention of depressive symptoms in the menopause transition: A randomized clinical trial. JAMA Psychiatry, 2018.

Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS. Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial. JAMA Psychiatry. 2018;75(2):149–157. doi:10.1001/jamapsychiatry.2017.3998

Gudipally PR, Sharma GK. Premenstrual Syndrome. [Updated 2022 Jul 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-.

Hernández-Hernández OT, Martínez-Mota L, Herrera-Pérez JJ, Jiménez-Rubio G. Role of Estradiol in the Expression of Genes Involved in Serotonin Neurotransmission: Implications for Female Depression. Curr Neuropharmacol. 2019;17(5):459-471. doi: 10.2174/1570159X16666180628165107. PMID: 29956632; PMCID: PMC6520586.

Jacobsen JP,  Krystal  AD,  Krishnan  KR, Caron MG: Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment- Resistant Depression: Clinical and Preclinical Rationale. Trends Pharmacol Sci. 2016 Nov;37(11):933–944. doi: 10.1016/j.tips.2016.09.001. Epub 2016 Sep 28.

Jovanovic H, Kocoska-Maras L, Rådestad AF, Halldin C, Borg J, Hirschberg AL, et al: Effects of estrogen and testosterone treatment on serotonin transporter binding in the brain of surgically postmenopausal women - a PET study. Neuroimage 2015;106:47–54.

McEwen BS, Akama KT, Spencer-Segal JL, Milner TA, Waters EM. Estrogen effects on the brain: actions beyond the hypothalamus via novel mechanisms. Behav Neurosci. 2012 Feb;126(1):4-16. doi: 10.1037/a0026708. PMID: 22289042; PMCID: PMC3480182..

 Paul SM, Pinna G, Guidotti A. Allopregnanolone: From molecular pathophysiology to therapeutics. A historical perspective. Neurobiol Stress. 2020 Mar 14;12:100215. doi: 10.1016/j.ynstr.2020.100215. PMID: 32435665; PMCID: PMC7231972.

Turkmen S, Backstrom T, Wahlstrom G, Andreen L, Johansson IM. Tolerance to allopregnanolone with focus on the GABA-A receptor. Br J Pharmacol. 2011 Jan;162(2):311-27. doi: 10.1111/j.1476-5381.2010.01059.x. PMID: 20883478; PMCID: PMC3031054.

 

Perimenopause causes and treatment

 Brink HV, Chizen D, Hale G, Baerwald A. Age-related changes in major ovarian follicular wave dynamics during the human menstrual cycle. Menopause 2013;20:1243–1254 [PubMed] [Google Scholar]

Burger HG, Dudley E, Mamers P, Groome N, Robertson DM. Early follicular phase serum FSH as a function of age: The roles of inhibin B, inhibin A and estradiol. Climacteric 2000;3:17–24 [PubMed] [Google Scholar]

Goletiani NV, Keith DR, Gorsky SJ. Progesterone: review of safety for clinical studies. Exp Clin Psychopharmacol. 2007 Oct;15(5):427-44. doi: 10.1037/1064-1297.15.5.427. PMID: 17924777.

Hale GE, Hughes CL, Burger HG, Robertson DM, Fraser IS. Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition. Menopause 2009;16:50–59 [PubMed] [Google Scholar]

Harlow SD, Gass M, Hall JE, et al.. Executive summary of the Stages of Reproductive Aging Workshop +10: Addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012;97:1159–1168 PubMed] 

Leonetti HB, Landes J, Steinberg D, Anasti JN. Transdermal progesterone cream as an alternative progestin in hormone therapy. Altern Ther Health Med. 2005 Nov-Dec;11(6):36-8. PMID: 16320858.

Leonetti HB, Wilson KJ, Anasti JN. Topical progesterone cream has an antiproliferative effect on estrogen-stimulated endometrium. Fertil Steril. 2003 Jan;79(1):221-2. doi: 10.1016/s0015-0282(02)04542-9. PMID: 12524095. 

Metcalf MG, Donald RA. Fluctuating ovarian function in a perimenopausal women. N Z Med J. 1979 Jan 24;89(628):45-7. PMID: 285373.

Metcalf MG. The approach of menopause: a New Zealand study. N Z Med J. 1988 Mar 9;101(841):103-6. PMID: 3132662.

Moen MH, Kahn H, Bjerve KS, Halvorsen TB. Menometrorrhagia in the perimenopause is associated with increased serum estradiol. Maturitas. 2004 Feb 20;47(2):151-5. doi: 10.1016/s0378-5122(03)00250-0. PMID: 14757274.

Prior JC, Hitchcock CL. The endocrinology of perimenopause: need for a paradigm shift. Front Biosci (Schol Ed). 2011 Jan 1;3(2):474-86. doi: 10.2741/s166. PMID: 21196391.

Prior JC. Progesterone for Symptomatic Perimenopause Treatment - Progesterone politics, physiology and potential for perimenopause. Facts Views Vis Obgyn. 2011;3(2):109-20. PMID: 24753856; PMCID: PMC3987489.

Prior, J.C., Cameron, A., Fung, M. et al. Oral micronized progesterone for perimenopausal night sweats and hot flushes a Phase III Canada-wide randomized placebo-controlled 4 month trial. Sci Rep 13, 9082 (2023). https://doi.org/10.1038/s41598-023-35826-w

Prior, Jerilynn and Cameron, Andrea and Fung, Michelle and Hitchcock, Christine L. and Janssen, Patricia and Lee, Terry and Singer, Joel, Oral Micronized Progesterone for Perimenopausal Night Sweats and Hot Flushes: A 12-Week Randomized Phase III Canada-Wide Clinical Trial (January 10, 2020).

Prior, Jerilynn C. "Clearing confusion about perimenopause." BC Med J 47.10 (2005): 538-42.

Regidor PA. Progesterone in Peri- and Postmenopause: A Review. Geburtshilfe Frauenheilkd. 2014;74(11):995-1002. doi:10.1055/s-0034-1383297

Ren B, Zhu Y. A New Perspective on Thyroid Hormones: Crosstalk with Reproductive Hormones in Females. International Journal of Molecular Sciences. 2022; 23(5):2708. https://doi.org/10.3390/ijms23052708

Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996;81:1495–1501 [PubMed] [Google Scholar]

Santoro N, Cedars M, Hansen K. AMH, FSH and AFC: The ABC's of ovarian reserve testing for the generalist. ACOG Update 2015;41 [Google Scholar]

Santoro N, Crawford SL, Lasley WL, et al.. Factors related to declining luteal function in women during the menopausal transition. J Clin Endocrinol Metab 2008;93:1711–1721 [PMC free article] [PubMed] [Google Scholar]

Santoro N, Isaac B, Neal-Perry G, et al.. Impaired folliculogenesis and ovulation in older reproductive aged women. J Clin Endocrinol Metab 2003;88:5502–5509 [PubMed] [Google Scholar]

Santoro N, Randolph JF., Jr Reproductive hormones and the menopause transition. Obstet Gynecol Clin North Am 2011;38:455–466 [PMC free article] [PubMed] [Google Scholar]

Santoro N. Perimenopause: From Research to Practice. J Womens Health (Larchmt). 2016 Apr;25(4):332-9. doi: 10.1089/jwh.2015.5556. Epub 2015 Dec 10. PMID: 26653408; PMCID: PMC4834516.

Sherman BM, West JH, Korenman SG. The menopausal transition: Analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women. J Clin Endocrinol Metab 1976;42:629–636 [PubMed] [Google Scholar]

Soules MR, Sherman S, Parrott E, et al.. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric 2001;4:267–272 [PubMed] 

Stanczyk FZ, Paulson RJ, Roy S. Percutaneous administration of progesterone: blood levels and endometrial protection. Menopause. 2005 Mar;12(2):232-7. doi: 10.1097/00042192-200512020-00019. PMID: 15772572.

The aging female reproductive axis II: ovulatory changes with perimenopause

The Pregnenolone Steal: A Closer Look at this Popular Concept – Dr Fiona McCulloch

Weiss G. Menstrual irregularities and the perimenopause. J Soc Gynecol Investig. 2001 Jan-Feb;8(1 Suppl Proceedings):S65-6. doi: 10.1016/s1071-5576(00)00113-1. PMID: 11223378. 

 Zhao FY, Fu QQ, Spencer SJ, Kennedy GA, Conduit R, Zhang WJ, Zheng Z. Acupuncture: A Promising Approach for Comorbid Depression and Insomnia in Perimenopause. Nat Sci Sleep. 2021 Oct 12;13:1823-1863. doi: 10.2147/NSS.S332474. PMID: 34675729; PMCID: PMC8520448.

Ziomkiewicz A, Pawlowski B, Ellison PT, Lipson SF, Thune I, Jasienska G. Higher luteal progesterone is associated with low levels of premenstrual aggressive behavior and fatigue. Biol Psychol. 2012 Dec;91(3):376-82. doi: 10.1016/j.biopsycho.2012.08.001. Epub 2012 Aug 10. PMID: 22906865.

 

HRT Risks and Benefits

Campagnoli, C., et al. 2005. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J. Steroid Biochem. Mol. Biol., 96 (2), 95–108. URL:

Darj, S. Nilsson, O. Axelsson, D. Hellberg, Clinical and endometrial effects of oestradiol and progesterone in post-menopausal women, Maturitas, Volume 13, Issue 2, 1991, Pages 109-115

Dennerstein L, Spencer-Gardner C, Gotts G, Brown JB, Smith MA, Burrows GD. Progesterone and the premenstrual syndrome: a double blind crossover trial. Br Med J (Clin Res Ed). 1985 Jun 1;290(6482):1617-21. doi: 10.1136/bmj.290.6482.1617. PMID: 3924191; PMCID: PMC1415816

Du JY, Sanchez P, Kim L, Azen CG, Zava DT, Stanczyk FZ. Percutaneous progesterone delivery via cream or gel application in postmenopausal women: a randomized cross-over study of progesterone levels in serum, whole blood, saliva, and capillary blood. Menopause. 2013 Nov;20(11):1169-75. doi: 10.1097/GME.0b013e31828d39a2. PMID: 23652031.

Effects of hormone replacement therapy on endometrial histology in postmenopausal women.

Ettinger B: ”Reduced mortality associated with long-term postmenopausal estrogen therapy.” Obstetrics and Gynecology jan. 1996;87(1):6-12.

Fitzpatrick LA m. fl: ”Comparison of regimens containing oral micronized progesterone of medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey.” Journal of Women's Health Gender Based Medicine maj 2000;9(4):381-387

Fournier A, Berrino F, Clavel-Chapelon F: ”Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.” Breast Cancer Research and Treatment årgång 107, nr 1 jan. 2008:103-111.

Fournier A, Mesrine S, Dossus L, Boutron-Ruault MC, Clavel-Chapelon F, Chabbert-Buffet N. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Res Treat. 2014 Jun;145(2):535-43. doi: 10.1007/s10549-014-2934-6. E

Fournier et al, “Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer,” J Clin Oncol 2008 Mar 10;26(8):1260-8.

Fournier et al, “Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort,” Int J Cancer 2005 Apr 10;114(3):448-54.

Gadducci, A., Biglia, N., Cosio, S., Sismondi, P., and Genazzani, A.R. Progestogen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue. Gynecol Endocrinol. 2009; 25: 807–815 ([Review])

Goletiani, N.V., Keith, D.R., and Gorsky, S.J. Progesterone: review of safety for clinical studies. Exp Clin Psychopharmacol. 2007; 15: 427–444

Gompel, A. Micronized progesterone and its impact on the endometrium and breast vs. progestogens. Climacteric. 2012; 15: 18–25

Kim, S.E., Min, JS., Lee, S. et al. Different effects of menopausal hormone therapy on non-alcoholic fatty liver disease based on the route of estrogen administration. Sci Rep 13, 15461 (2023). https://doi.org/10.1038/s41598-023-42788-6

L’hermite, M. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT. Climacteric. 2013; 16: 44–53

Miller VM, Naftolin F, Asthana S, Black DM, Brinton EA, Budoff MJ, Cedars MI, Dowling NM, Gleason CE, Hodis HN, Jayachandran M, Kantarci K, Lobo RA, Manson JE, Pal L, Santoro NF, Taylor HS, Harman SM. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Menopause. 2019 Sep;26(9):1071-1084. doi: 10.1097/GME.0000000000001326. PMID: 31453973; PMCID: PMC6738629.

Newson LR, Lass A. Effectiveness of transdermal oestradiol and natural micronised progesterone for menopausal symptoms. Br J Gen Pract. 2018 Oct;68(675):499-500. doi: 10.3399/bjgp18X699353. PMID: 30262631; PMCID: PMC6146001.

Regidor PA. Progesterone in Peri- and Postmenopause: A Review. Geburtshilfe Frauenheilkd. 2014 Nov;74(11):995-1002. doi: 10.1055/s-0034-1383297. PMID: 25484373; PMCID: PMC4245250.

Schierbeck, Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial, BMJ 2012; 345 doi: (Published 09 October 2012)

Simon JA. What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. Climacteric. 2012 Apr;15 Suppl 1:3-10. doi: 10.3109/13697137.2012.669332. PMID: 22432810.

Somboonporn W, Panna S, Temtanakitpaisan T, Kaewrudee S, Soontrapa S. Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: Systematic review and meta-analysis. Menopause 2011;18:1060–1066 

Studd J. Hormone therapy for reproductive depression in women. Post Reproductive Health. 2014;20(4):132-137. doi:10.1177/2053369114557883

Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric. 2016 Aug;19(4):316-28. doi: 10.1080/13697137.2016.1187123. Epub 2016 Jun 9. PMID: 27277331.

Taylor MB, Gutierrez MJ. Absorption, bioavailability, and partner transfer of estradiol from a topical emulsion. Pharmacotherapy. 2008 Jun;28(6):712-8. doi: 10.1592/phco.28.6.712. PMID: 18503399.

 The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1996 Feb 7;275(5):370-5. doi: 10.1001/jama.1996.03530290040035. PMID: 8569016.

Vongpatasin W m. fl: ”Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women.” Journal of the American College of Cardiology 2003;41:1358-1363.

 

Progesterone and bone density

Seifert-Klauss V, Prior JC. Progesterone and bone: actions promoting bone health in women. J Osteoporos. 2010 Oct 31;2010:845180. doi: 10.4061/2010/845180. PMID: 21052538; PMCID: PMC2968416. 

 

HRT Alzheimer’s and Neurodegenerative Disease

Kim YJ, Soto M, Branigan GL, Rodgers K, Brinton RD. Association between menopausal hormone therapy and risk of neurodegenerative diseases: Implications for precision hormone therapy. Alzheimers Dement (N Y). 2021 May 13;7(1):e12174. doi: 10.1002/trc2.1217

 Vinogradova Y, Dening T, Hippisley-Cox J, Taylor L, Moore M, Coupland C. Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases. BMJ. 2021 Sep 29;374:n2182. doi: 10.1136/bmj.n2182. PMID: 3458

 

HRT and Colorectal Cancer

Julia D Labadie, Tabitha A Harrison, Barbara Banbury, Efrat L Amtay, Sonja Bernd, Hermann Brenner, Daniel D Buchanan, Peter T Campbell, Yin Cao, Andrew T Chan, Jenny Chang-Claude, Dallas English, Jane C Figueiredo, Steven J Gallinger, Graham G Giles, Marc J Gunter, Michael Hoffmeister, Li Hsu, Mark A Jenkins, Yi Lin, Roger L Milne, Victor Moreno, Neil Murphy, Shuji Ogino, Amanda I Phipps, Lori C Sakoda, Martha L Slattery, Melissa C Southey, Wei Sun, Stephen N Thibodeau, Bethany Van Guelpen, Syed H Zaidi, Ulrike Peters, Polly A Newcomb, Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location, JNCI Cancer Spectrum, Volume 4, Issue 5, October 2020, pkaa042, https://doi.org/10.1093/jncics/pkaa042